User:Lan.wang17/Jon Zifferblatt

This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft.

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL
Easy tools: Citation bot (help) | Advanced: Fix bare URLs
This page was last edited by Timrollpickering (talk | contribs) 5 years ago. (Update timer)

Finished writing a draft article? Are you ready to request an experienced editor review it for possible inclusion in Wikipedia? Submit your draft for review!

Jon Zifferblatt MD/MPH/MBA, is healthcare professional and Editor-in-Chief of the China Pharmaceutical and Biotechnology Review. He is the managing director of General Biologic (GBI), a Shanghai-based consulting and data intelligence company^[1] and currently serves as the Vice Chair of the Shanghai American Chamber of Commerce- Healthcare Committee^[2]. Previously, Zifferblatt was the VP of ChinaVest, a merchant bank based in Shanghai. He received his B.S. education from Stanford and a MBA/MPH from University of Berkeley's Haas School of Business.^[3]

Zifferblatt frequently speaks and writes about China's pharmaceutical and healthcare space. He is a regularly contributor for the Pharmaceutical Executive magazine.^[4] Zifferblatt was also interviewed in Swedish newswire, Sydsvenskan, about the impact of China's healthcare reform.^[5]

References

External links

[1]

[1] ttp://www.businessweek.com/globalbiz/content/jun2009/gb20090619_223752.htm

[2] ttp://www.amcham-shanghai.org/amchamportal/committees/Committeeabout.aspx?CommitteeID=26

[3] ttp://www.amcham-shanghai.org/amchamportal/committees/Committeeabout.aspx?CommitteeID=26

[4] ttp://pharmexec.findpharma.com/pharmexec/China+Chartways/Lifting-the-Veil/ArticleStandard/Article/detail/695698

[5] ttp://www.sydsvenskan.se/varlden/article1312016/Lagre-vinster-ska-ge-vard-aven-at-fattiga.html

[1]

[2]

[3]

[4]

[5]